Market Overview - The biopharmaceutical sector experienced a decline of 1.72% on December 2, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Individual Stock Performance - Dongbao Bio (300239) closed at 5.80, up 1.05% with a trading volume of 93,700 shares and a transaction value of 53.99 million yuan [1] - Aopumai (688293) saw a significant drop of 8.01%, closing at 50.32 with a trading volume of 33,400 shares and a transaction value of 171 million yuan [2] - Other notable declines included Kanghong Pharmaceutical (002773) down 3.78% and Watson Bio (300142) down 3.17% [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 456 million yuan from institutional investors, while retail investors saw a net inflow of 270 million yuan [2] - Notable stocks with significant capital inflows included He Yuan Bio (688765) with a net inflow of 17.69 million yuan from institutional investors [3] - Conversely, stocks like Rongchang Bio (688331) and Shenzhou Cell (688520) also saw mixed capital flows, indicating varied investor sentiment [3]

Core Viewpoint - Nearshore Protein (688137.SH) is currently trading at 40.62 yuan, reflecting a decline of 3.52% and is in a state of breaking its initial public offering price [1] Group 1: Company Overview - Nearshore Protein was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 29, 2022, with an initial offering price of 106.19 yuan per share [1] - The company issued a total of 17,543,860 shares during its IPO, with Minsheng Securities Co., Ltd. acting as the lead underwriter [1] Group 2: Fundraising and Financials - The total amount raised from the IPO was 1,862.9825 million yuan, with a net amount of 1,742.1958 million yuan after deducting issuance costs [1] - The net fundraising amount exceeded the original plan by 242.1958 million yuan [1] - The company initially aimed to raise 1,500 million yuan, which was intended for projects related to core diagnostic materials, innovative diagnostic reagent industrialization, R&D center construction, and working capital supplementation [1] Group 3: Issuance Costs - The total issuance costs for the IPO amounted to 120.7867 million yuan, with Minsheng Securities receiving underwriting and sponsorship fees of 98.4217 million yuan [1]

证券代码：688137 证券简称：近岸蛋白 公告编号：2025-055 苏州近岸蛋白质科技股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于 2025 年 10 月 13 日召开第二届董事会第十三次临时会议，审议通过了 《关于延长股份回购期限的议案》，同意公司原回购实施期限延长 6 个月，延期至 2026 年 4 月 13 日止，除回购实施期限延长外，公司回购股份方案的其他内容未发 生变化。具体内容详见公司于 2025 年 10 月 14 日在上海证券交易所网站 （www.sse.com.cn）披露的《苏州近岸蛋白质科技股份有限公司关于延长股份回 购实施期限的公告》（公告编号：2025-041） 二、回购股份的进展情况 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购股份期间，应当在每个月的前 3 个交 易日内公告截至上月末的回购进展情况。现将公司回购股份进展情况公告如下： 截至 2025 年 11 月 30 日，公司暂未开展 ...

Core Viewpoint - The company announced a share repurchase plan approved at the shareholder meeting on October 15, 2024, with a budget of 10 million to 20 million yuan for reducing registered capital, with a repurchase price not exceeding 30.68 yuan per share [1] Group 1 - The initial repurchase period was set to end on October 15, 2025, but was extended by six months to April 13, 2026 [1] - As of November 30, 2025, the company has not yet initiated the share repurchase and will implement it at an opportune time [1]

Group 1 - The core point of the announcement is that shareholders holding less than 5% of the company's shares plan to reduce their holdings due to operational and funding needs, with a reduction period starting three trading days after the announcement and lasting for three months [2][3]. - The shareholders involved in the reduction are Nanjing Jinli Venture Capital Partnership, Suzhou Jinling Venture Capital Partnership, and Shanghai Pujin Technology Development Partnership, collectively holding 140,111 shares, which is approximately 0.1997% of the total share capital [2]. - The reduction will be executed through methods such as centralized bidding and block trading, with the selling price determined by market conditions [2][3]. Group 2 - The shareholders have made commitments regarding their shareholding intentions and reduction plans, ensuring compliance with relevant laws and regulations, including a three-day prior notice before any reduction [3]. - The company confirms that the reduction plan will not lead to a change in control of the company and is consistent with previously disclosed commitments [4]. - The announcement emphasizes that the reduction plan aligns with the regulations set forth by the Shanghai Stock Exchange and other relevant authorities, ensuring that the shareholders will fulfill their disclosure obligations during the reduction period [4].

股东南京金溧创业投资合伙企业（有限合伙）（以下简称"南京金溧"）和 苏州金灵创业投资合伙企业（有限合伙）（以下简称"苏州金灵"）为一致行动 人关系，共计持有公司 29,111 股股份，合计占公司总股本比例为 0.0415%；股 东上海普近科技发展合伙企业（有限合伙）（以下简称"上海普近"）持有公司 111,000 股股份，占公司总股本比例为 0.1582%。 减持计划的主要内容 南京金溧、苏州金灵和上海普近因自身经营发展和资金需求计划拟通过集中 竞价、大宗交易等方式减持所持有的公司部分股份，股东的减持价格按照市场价 格确定，减持期间为自本公告披露之日起 3 个交易日后的三个月内。 相关股东均为持股 5%以下股东，均不属于公司控股股东、实际控制人或董 监高，本次披露减持计划为履行在招股说明书中载明的减持公司股份将提前 3 个交易日公告的承诺。 在上述股东减持期间，若有送股、资本公积转增股本、配股等股份变动事项， 则应对减持数量进行相应调整。 证券代码：688137 证券简称：近岸蛋白 公告编号：2025-054 苏州近岸蛋白质科技股份有限公司 关于持股 5%以下股东减持股份计划公告 本公司董事会、全体董事及相关 ...

Summary of Key Points Core Viewpoint - On November 27, several A-share listed companies disclosed their shareholding changes, with notable increases in holdings from some companies and reductions from others, indicating varying levels of confidence among stakeholders in the market [1]. Group 1: Shareholding Increases - Mindray Medical's actual controller and chairman, Li Xiting, plans to increase his stake in the company by 200 million yuan [2]. - Everbright Bank saw Citic Financial Assets increase its holdings in both A-shares and H-shares by a total of 1% from July 24 to November 27 [2]. - MaiDe Medical's chairman and actual controller, Lin Junhua, proposed a share buyback plan ranging from 20 million to 40 million yuan [2]. Group 2: Shareholding Reductions - Yonghe Intelligent Control's shareholders plan to collectively reduce their holdings by no more than 3.29% [2]. - Perfect World’s actual controller, Chi Yufeng, intends to reduce his stake by no more than 1.70% [2]. - XueNeng Technology's shareholder, Shanghang Xingyuan, plans to reduce holdings by no more than 1.6816% [2]. - Hongxiang New Materials' controlling shareholder, Hongbo Chemical, has cumulatively reduced its stake by 3% recently [2]. - Nearshore Protein's shareholders plan to collectively reduce their holdings by no more than 0.1997% [2]. - Aerospace Hongtu's director and executive, Huang Yongbo, plans to reduce his stake by no more than 0.0019% [2]. - Yidelong's shareholder, Wang Ming, intends to reduce his holdings by no more than 2% [2]. - Zhongman Petroleum's shareholders plan to collectively reduce their holdings by no more than 3% [2]. - Innovation New Materials' shareholder, Hualian Group, plans to reduce its stake by no more than 1% [2]. - Saiwei Electronics has seen the National Integrated Circuit Industry Investment Fund reduce its holdings by 6.4278 million shares [2]. - Zhongzhi Technology's shareholder, Zhongzhi Investment, plans to reduce its stake by no more than 0.76% [2]. - Jiangsu Boyun's shareholder, Lansan Venture Capital, intends to reduce its holdings by no more than 1% [2]. - Huasheng Lithium's deputy general manager, Zhang Conghe, plans to reduce his stake by no more than 0.31% [2]. - Huasheng Electric's shareholder, Dunxing Jucai, reduced its holdings by 444,500 shares between November 25 and 27 [2]. - Matrix Technology's shareholder, Li Jun, plans to reduce his stake by no more than 0.22% [2].

Core Points - The company Nearshore Protein announced on November 27 that its shareholders plan to reduce their holdings starting from December 4, 2025, over a period of three months [1] Shareholder Reduction Plans - Nanjing Jinli Venture Capital Partnership intends to reduce its holdings by no more than 13,700 shares, representing 0.0196% of the company's total share capital [1] - Suzhou Jinling Venture Capital Partnership plans to reduce its holdings by no more than 15,400 shares, accounting for 0.0219% of the total share capital [1] - Shanghai Pujin Technology Development Partnership aims to reduce its holdings by no more than 111,000 shares, which is 0.1582% of the total share capital [1] - The reduction prices will be determined based on market conditions, and the reason for the reduction is stated as the shareholders' own operational development needs [1]

南财智讯11月27日电，近岸蛋白公告，南京金溧创业投资合伙企业（有限合伙）、苏州金灵创业投资合 伙企业（有限合伙）和上海普近科技发展合伙企业（有限合伙）因自身经营发展需求，拟通过集中竞 价、大宗交易等方式减持公司股份。其中，南京金溧拟减持不超过1.37万股，占公司总股本比例不超过 0.0196%；苏州金灵拟减持不超过1.54万股，占公司总股本比例不超过0.0219%；上海普近拟减持不超过 11.1万股，占公司总股本比例不超过0.1582%。减持期间为2025年12月4日至2026年3月3日，减持价格将 按照市场价格确定。上述股东均不属于公司控股股东、实际控制人或董监高，本次减持计划系履行招股 说明书中关于减持前3个交易日公告的承诺。减持计划实施存在不确定性，不会对公司治理结构和持续 经营产生重大影响。 ...

Summary of Key Points Core Viewpoint - The announcement from Nearshore Protein indicates that certain shareholders plan to reduce their holdings within a specified timeframe, which may impact the stock's liquidity and market perception [1] Shareholder Actions - Shareholders Nanjing Jinli and Suzhou Jinling, holding a combined 0.0415% of shares, plan to reduce their holdings by a total of 13,735 shares and 15,376 shares respectively between December 4, 2025, and March 3, 2026 [1] - Shareholder Shanghai Pujin, holding 0.1582% of shares, intends to reduce its entire holding of 111,000 shares during the same period [1]